Eisai and Biogen Announce Approval of Alzheimer’s Treatment LEQEMBI® in Israel

Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito) and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusetts, CEO: Christopher...

July 12, 2024 | Friday | News
AHB-137 Receives Breakthrough Therapy Designation from NMPA, Paving the Way for Faster Access to Chronic Hepatitis B Treatment

AHB-137 gains Breakthrough Therapy Designation (BTD) from the NMPA based on Phase 1/Phase2a clinical trial data demonstrating safety and efficacy. BTD...

July 11, 2024 | Thursday | News
BioArctic AB’s Partner Eisai Announces Approval of Leqembi® (樂意保®) for Alzheimer’s Disease Treatment in Hong Kong

BioArctic AB  is pleased to announce that its partner, Eisai, has received approval from the Department of Health in Hong Kong for Leqembi® (bra...

July 11, 2024 | Thursday | News
Daiichi Sankyo Expands European Presence with New Oncology Affiliate in Greece

Daiichi Sankyo  announced that it has opened a new affiliate for its oncology business in Athens, Greece. The establishment highlights the company&r...

July 10, 2024 | Wednesday | News
HepaRegeniX Secures €15M Series C Funding to Advance Liver Regeneration Therapy HRX-215

Funds to support Phase Ib clinical trial of HRX-215 in the US and an international multicenter Phase IIa clinical trial in liver regeneration Elias Pa...

July 10, 2024 | Wednesday | News
Roche Receives CE Mark for Accu-Chek® SmartGuide CGM Solution, Empowering Diabetes Management in Europe

Roche  announced  that it has received the CE Mark for its Accu-Chek® SmartGuide continuous glucose monitoring (CGM) solution. This signifi...

July 09, 2024 | Tuesday | News
Apriori Bio Secures $1.1 Million from CEPI to Enhance AI-Driven Vaccine Platform Against Evolving Viruses

Biotechnology company Apriori Bio has been awarded US $1.1 million from CEPI to advance its biology-informed artificial intelligence platform Octavi...

July 09, 2024 | Tuesday | News
Eli Lilly to Acquire Morphic Holding for $3.2 Billion, Expanding Gastroenterology Portfolio

Eli Lilly and Company (NYSE: LLY) and Morphic Holding, Inc. (NASDAQ: MORF)  announced a definitive agreement for Lilly to acquire Mor...

July 09, 2024 | Tuesday | News
Rafarma Pharmaceuticals and Woods Medical Care to Establish Joint Industrial Venture in South Korea's Busan Technology Park

Rafarma Pharmaceuticals is pleased to announce the signing of a preliminary agreement to establish a joint industrial venture in Busan Technology Park (S...

July 04, 2024 | Thursday | News
Boehringer Ingelheim and OSE Immunotherapeutics Advance SIRPα Immuno-Oncology Program to Phase 1b Clinical Trials

Boehringer Ingelheim and OSE Immunotherapeutics SA (OSE), a clinical stage biotech company (ISIN: FR0012127173; Mnemo: OSE), announced that Boehringer wi...

July 04, 2024 | Thursday | News
Merck and and Orion Announce Exercise of Option for Exclusive Global License of Opevesostat, Advancing Prostate Cancer Treatment

Merck  known as MSD outside of the United States and Canada, and Orion Corporation announced that notice has been provided of the mutual exercise of...

July 02, 2024 | Tuesday | News
Dawn Health Partners with Merck to Develop Digital Solution for Growth Hormone Disorders

Dawn Health, the digital health company pioneering patient-first innovation, has announced they are working with leading global pharmaceutical company, M...

July 01, 2024 | Monday | News
AbbVie Acquires Celsius Therapeutics to Advance Innovative IBD Treatments

AbbVie (NYSE: ABBV) announced  the acquisition of Celsius Therapeutics, Inc. ("Celsius"), a privately held biotechnology company pioneering new...

June 28, 2024 | Friday | News
WHO Awards Prequalification to Roche's HPV Test for Broad Use, Enhancing Global Cervical Cancer Screening

The World Health Organization (WHO) has awarded Roche's human papillomavirus (HPV) test prequalification designations for use on the cobas 5800 System ...

June 27, 2024 | Thursday | News

Survey Box

Poll of the Week

Which area of biopharmaceutical research excites you the most?

× Please select an option to participate in the poll.
Processing...
× You have successfully cast your vote.
 {{ optionDetail.option }}  {{ optionDetail.percentage }}%
 {{ optionDetail.percentage }}% Complete
More polls
Stay Connected

Sign up to our free newsletter and get the latest news sent direct to your inbox

© 2025 Biopharma Boardroom. All Rights Reserved.

Show

Forgot your password?

Show

Show

Lost your password? Please enter your email address. You will receive a link to create a new password.

Back to log-in

Close